A new study has made significant progress toward slowing or even halting the progression of Alzheimer's disease by selectively targeting a protein and possibly removing protein deposits that are common markers of the disease.
The research, which was reported on May 27 in Nature Neuroscience, aimed to increase the brain's ability to eliminate amyloid plaques, a characteristic of Alzheimer's disease, by changing the plexin-B1 protein. Reactive astrocytes, a subpopulation of brain cells activated in response to disease or trauma, were crucial to this process.
(Photo : by ALAIN JOCARD/AFP via Getty Images)
They help regulate the area around amyloid plaques, which affects how other brain cells can access and eliminate these harmful deposits.
To comprehend the molecular and cellular causes of the disease, complicated data comparing healthy people to those with Alzheimer's disease served as the driving force behind the research.
One of the study's lead authors, Hongyan Zou, PhD, a professor of neurosurgery and neuroscience at Icahn Mount Sinai, emphasized the wider implications of their findings. They say they open up new avenues for research on Alzheimer's disease and highlight the significance of cellular interactions in the development of treatments for neurodegenerative diseases.
The research highlights the significance of plexin-B1 in Alzheimer's disease and highlights the potential of targeted therapeutics to impede the illness's advancement.
Although the research team's findings represent a major advancement in the fight against Alzheimer's, they stress that further study is necessary before these findings can be used to develop patient treatments.
Alzheimer's Research in the UK
The ground-breaking study came just a few days after, on Tuesday, May 14, more than 20,000 people reportedly offered their time to support critical dementia therapy research in the UK.
It is anticipated that the effort, spearheaded by the University of Cambridge in partnership with the Alzheimer's Society, will expedite the development of critically needed medicines for dementia.
Given the disease's startling prevalence and significant effects on people and society worldwide, dementia research is essential.
The UK Alzheimer's Society estimates that 982,000 individuals in the country are living with dementia at the moment, and by 2040, that number is expected to rise to 1.4 million.
Americans and Dementia Treatment
Based on other recent research, approximately 6 million Americans may be at risk of APOE4-related hereditary Alzheimer's disease, which strikes at a startling 95% of people by the time they are 65.
These results go against what is generally accepted and imply that the APOE4 gene may be the main cause of hereditary Alzheimer's disease rather than just a risk factor. People who receive the same APOE gene from both parents inherit this genetic predisposition through a genetic lottery. The researchers came to these conclusions after assessing a wide cohort of people and examining data from clinical cohorts and brain donors in Europe and the US.
Current dementia treatments are not very effective, and despite recent advancements, most novel strategies have not passed clinical trials.
Drugs tested while symptoms are already severe can be less effective, which is one of the main challenges. Therefore, it's imperative to comprehend dementia's early phases and create interventions before symptoms manifest.
Related Article: AI Predicts, Detects Alzheimer's Disease in New Study
